Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy (BIS-Program)
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Terminated
Abandon of the partner, ROCHE
Other terminated trials from Gustave Roussy, Cancer Campus, Grand Paris
- Biliary Tract Cancer · Phase PHASE2 · Feb 2025
- Metastatic Renal Cell Carcinoma · Phase NA · May 2024
- Ovarian Cancer · Phase PHASE1/PHASE2 · Apr 2024
- Very High Risk Neuroblastoma · Phase PHASE2 · Mar 2024
- Peritoneal Carcinomatosis · Phase PHASE2 · Feb 2024
See all terminations from Gustave Roussy, Cancer Campus, Grand Paris
Listed as NCT05180006, this PHASE2 trial focuses on Breast Cancer and remains terminated or withdrawn. Sponsored by Gustave Roussy, Cancer Campus, Grand Paris, it has been updated 7 times since 2022, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Jan 2026 — Present [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Sep 2024 — Jan 2026 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
Apr 2023 — May 2024 [monthly]
Recruiting PHASE2
▶ Show 2 earlier versions
-
Apr 2022 — Apr 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Feb 2022 — Apr 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Gustave Roussy, Cancer Campus, Grand Paris
- Hoffmann-La Roche
For direct contact, visit the study record on ClinicalTrials.gov .